文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-pentixafor PET/CT半定量测量在WM/LPL疗效评估中的价值

Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
PubMed 文献 · EJNMMI Res · 2021-10-29

结果显示68Ga-pentixafor PET/CT基于∆TLUCXCR4%、∆MTVCXCR4%、∆SUVpeak%的疗效评估与临床缓解、单克隆蛋白及IgM缓解显著直接相关(p<0.01),而18F-FDG PET/CT评估与临床缓解无关(p>0.05)。

要点

  • 68Ga-pentixafor PET/CT半定量指标与WM/LPL临床缓解、单克隆蛋白及IgM缓解显著相关。
  • 18F-FDG PET/CT基于疗效的评估与临床缓解无显著相关。
  • 68Ga-pentixafor PET/CT在WM/LPL疗效评估中优于18F-FDG PET/CT。

核心结论

  • 68Ga-pentixafor PET/CT的半定量测量在WM/LPL疗效评估中优于18F-FDG PET/CT。

研究设计与样本

  • 采用MTV、TLGFDG和TLUCXCR4等半定量指标分析基于PET/CT的疗效,并与临床缓解、单克隆蛋白和IgM缓解进行相关性分析。

主要发现

  • 化疗后5例达完全缓解或非常好的部分缓解,8例达部分缓解或微小缓解,2例疾病进展。
  • 68Ga-pentixafor PET/CT基于∆TLUCXCR4%、∆MTVCXCR4%、∆SUVpeak%的疗效评估与临床缓解、单克隆蛋白及IgM缓解呈显著直接相关(p<0.01)。
  • 18F-FDG PET/CT基于疗效的评估与临床缓解无关(p>0.05)。

关键数值与推荐

  • 68Ga-pentixafor PET/CT疗效评估采用∆TLUCXCR4%、∆MTVCXCR4%、∆SUVpeak%等半定量指标。
  • 68Ga-pentixafor PET/CT指标与临床缓解、单克隆蛋白及IgM缓解的相关性p<0.01。
  • 18F-FDG PET/CT疗效评估与临床缓解的相关性p>0.05。

临床怎么用

  • 在WM/LPL疗效评估中可考虑采用68Ga-pentixafor PET/CT半定量指标辅助判断治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 68Ga-pentixafor PET/CT was reported to have a high sensitivity in detecting tumor involvement of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) in our previous study. We aimed to further investigate the semi-quantitative measurements of 68Ga-pentixafor PET/CT in response assessment in WM/LPL. METHODS: Fifteen patients with WM/LPL were recruited in a prospective cohort study and underwent both 68Ga-pentixafor and 18F-FDG PET/CT at baseline and post-treatment. PET/CT-based responses were analyzed with semi-quantitative assessments of metabolic tumor volume (MTV) and total lesions glycolysis/uptake (TLGFDG and TLUCXCR4), and the correlation between PET/CT-based response and clinical response, monoclonal protein and IgM response was analyzed. RESULTS: After chemotherapy, 5 patients had complete response or very good partial response, 8 had partial response or minimal response and 2 had progressive disease. In quantitative analysis, 68Ga-pentixafor PET/CT-based response (measured in ∆TLUCXCR4%, ∆MTVCXCR4%, ∆SUVpeak%) showed a significant direct correlation with clinical response, monoclonal protein and IgM response (p < 0.01). However, 18F-FDG PET/CT-based response was independent from clinical response (p > 0.05). CONCLUSIONS: The semi-quantitative measurements of 68Ga-pentixafor PET/CT outperformed 18F-FDG PET/CT in response assessment of WM/LPL.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Pan Q, Cao X, Luo Y, et al. Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. EJNMMI Res. 2021. PMID: 34714390. doi:10.1186/s13550-021-00852-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。